Dermapharm Holding SE (DMP) — Capital Reinvestment Ratio
Latest as of March 2026:
0.30x
Dermapharm Holding SE (DMP) has a Capital Reinvestment Ratio of 0.30x as of March 2026, meaning it reinvests 0% of its operating cash flow (€39.49 Million) in capital expenditures (€11.85 Million). See DMP cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.30x
Capex / Operating Cash Flow
Operating Cash Flow
€39.49 Million
EUR
Capital Expenditures
€11.85 Million
EUR
Data as of
Mar 2026
Most recent filing
Dermapharm Holding SE Capital Reinvestment Ratio (2014–2025)
This chart tracks Dermapharm Holding SE's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Dermapharm Holding SE (2014–2025)
Year-by-year Capital Reinvestment Ratio for Dermapharm Holding SE from 2014 to 2025. For live market cap and broader valuation context, see Dermapharm Holding SE market capitalisation.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.23x | €181.51 Million | €42.12 Million | ▲ +22.2% |
| 2024 | 0.19x | €201.38 Million | €38.24 Million | ▲ +0.3% |
| 2023 | 0.19x | €219.42 Million | €41.54 Million | ▲ +40.0% |
| 2022 | 0.14x | €288.53 Million | €39.01 Million | ▼ -44.7% |
| 2021 | 0.24x | €250.37 Million | €61.20 Million | ▼ -21.4% |
| 2020 | 0.31x | €131.10 Million | €40.80 Million | ▼ -32.6% |
| 2019 | 0.46x | €100.61 Million | €46.44 Million | ▲ +182.8% |
| 2018 | 0.16x | €159.13 Million | €25.97 Million | ▼ -81.1% |
| 2017 | 0.86x | €86.74 Million | €74.72 Million | ▲ +272.4% |
| 2016 | 0.23x | €76.78 Million | €17.76 Million | ▼ -37.5% |
| 2015 | 0.37x | €40.38 Million | €14.93 Million | ▼ -29.4% |
| 2014 | 0.52x | €54.26 Million | €28.42 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow